Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons

Neurobiology of Disease

Volumn 47, Issue 3, 2012, Pages 367-377

  Ulusoy, Ayse ^a   Björklund, Tomas ^a   Buck, Kerstin ^a   Kirik, Deniz ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Adeno associated virus; Short hairpin RNA; Transgenic mice; Tyrosine hydroxylase; VMAT2

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ARTICLE; CELL STRUCTURE; CYTOPLASM; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; EMBRYO; ENZYME ACTIVITY; IN VIVO STUDY; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ELECTROCHEMISTRY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; HYDROXYINDOLEACETIC ACID; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; RNA, SMALL INTERFERING; SEROTONIN; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84862303338     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.05.012     Document Type: Article

References (50)

1. Baptista M.J., O'Farrell C., Daya S., Ahmad R., Miller D.W., Hardy J., et al. Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J. Neurochem. 2003, 85(4):957-968. (May).
2. Birkmayer W., Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien. Klin. Wochenschr. 1961, 73:787-788. (Nov 10).
3. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 2007, 27(30):8138-8148. (Jul 25).
4. Caudle W.M., Colebrooke R.E., Emson P.C., Miller G.W. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci. 2008, 31(6):303-308. (Jun).
5. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007, 447(7148):1081-1086. (Jun 28).
6. Chan C.S., Gertler T.S., Surmeier D.J. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov. Disord. 2010, 25(Suppl. 1):S63-S70.
7. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364(9440):1167-1169. (Sep 25-Oct 1).
8. Chen L., Ding Y., Cagniard B., Van Laar A.D., Mortimer A., Chi W., et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 2008, 28(2):425-433. (Jan 9).
9. Chesselet M.F. Dopamine and Parkinson's disease: is the killer in the house?. Mol. Psychiatry 2003, 8(4):369-370. (Apr).
10. Chung C.Y., Koprich J.B., Hallett P.J., Isacson O. Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(52):22474-22479.
11. Colebrooke R.E., Humby T., Lynch P.J., McGowan D.P., Xia J., Emson P.C. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur. J. Neurosci. 2006, 24(9):2622-2630. (Nov).
12. Cyr M., Beaulieu J.M., Laakso A., Sotnikova T.D., Yao W.D., Bohn L.M., et al. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(19):11035-11040. (Sep 16).
13. Dong Z., Ferger B., Feldon J., Bueler H. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J. Neurobiol. 2002, 53(1):1-10. (Oct).
14. Eslamboli A., Romero-Ramos M., Burger C., Bjorklund T., Muzyczka N., Mandel R.J., et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007, 130(Pt 3):799-815. (Mar).
15. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J. Neurol. 2005, 252(Suppl. 4):IV37-IV42. (Oct).
16. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 2008, Elsevier, NY.
17. Galvin J.E. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol. 2006, 112(2):115-126. (Aug).
18. Grimm D. Production methods for gene transfer vectors based on adeno-associated virus serotypes. Methods 2002, 28:146-157.
19. Gundersen H.J., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 1987, 147:229-263.
20. Guzman J.N., Sanchez-Padilla J., Chan C.S., Surmeier D.J. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 2009, 29(35):11011-11019. (Sep 2).
21. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(5):1956-1961. (Mar 5).
22. Holloway R.G., Shoulson I., Fahn S., Kieburtz K., Lang A., Marek K., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 2004, 61(7):1044-1053. (Jul).
23. Hommel J.D., Sears R.M., Georgescu D., Simmons D.L., DiLeone R.J. Local gene knockdown in the brain using viral-mediated RNA interference. Nat. Med. 2003, 9(12):1539-1544. (Dec).
24. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53(Suppl. 3):S26-S36. (discussion S-8).
25. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 2002, 22(7):2780-2791. (Apr 1).
26. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(5):2884-2889. (Mar 4).
27. Klein R.L., King M.A., Hamby M.E., Meyer E.M. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 2002, 13(5):605-612. (Mar 20).
28. Lauwers E., Beque D., Van Laere K., Nuyts J., Bormans G., Mortelmans L., et al. Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol. Aging 2007, 28(2):248-257. (Feb).
29. Lee F.J., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 2001, 15(6):916-926. (Apr).
30. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(16):10813-10818. (Aug 6).
31. Maguire-Zeiss K.A., Short D.W., Federoff H.J. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?. Brain Res. Mol. Brain Res. 2005, 134(1):18-23. (Mar 24).
32. Mooslehner K.A., Chan P.M., Xu W., Liu L., Smadja C., Humby T., et al. Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol. Cell. Biol. 2001, 21(16):5321-5331. (Aug).
33. Mosharov E.V., Larsen K.E., Kanter E., Phillips K.A., Wilson K., Schmitz Y., et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62(2):218-229. (Apr 30).
34. Peng X., Tehranian R., Dietrich P., Stefanis L., Perez R.G. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J. Cell Sci. 2005, 118(Pt 15):3523-3530. (Aug 1).
35. Perez R.G., Hastings T.G. Could a loss of alpha-synuclein function put dopaminergic neurons at risk?. J. Neurochem. 2004, 89(6):1318-1324. (Jun).
36. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 2002, 22(8):3090-3099. (Apr 15).
37. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 2000, 342(20):1484-1491. (May 18).
38. Schmitz C., Hof P.R. Design-based stereology in neuroscience. Neuroscience 2005, 130:813-831.
39. Sidhu A., Wersinger C., Vernier P. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett. 2004, 565(1-3):1-5. (May 7).
40. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302(5646):841. (Oct 31).
41. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388(6645):839-840. (Aug 28).
42. Tehranian R., Montoya S.E., Van Laar A.D., Hastings T.G., Perez R.G. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. J. Neurochem. 2006, 99(4):1188-1196. (Nov).
43. Ulusoy A., Sahin G., Bjorklund T., Aebischer P., Kirik D. Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Mol. Ther. 2009, 17(9):1574-1584. (Sep).
44. Ulusoy A., Sahin G., Kirik D. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(29):13159-13164. (Jul 20).
45. West M.J. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 1999, 22:51-61.
46. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 2003, 54(1):93-101. (Jul).
47. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 2002, 8(6):600-606. (Jun).
48. Yamada M., Iwatsubo T., Mizuno Y., Mochizuki H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J. Neurochem. 2004, 91(2):451-461. (Oct).
49. Zhou W., Schaack J., Zawada W.M., Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 2002, 926(1-2):42-50. (Feb 1).
50. Zolotukhin S., et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999, 6:973-985.